Publications by authors named "Antje Van Lessen"

Claim this Profile
U
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Jaspal Kaeda, Frauke Ringel, Christian Oberender, Ken Mills, Concetta Quintarelli, Antje van Lessen

Leuk Lymphoma· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood sCD3⁻ CD4⁺ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma.
Anju Singh, Richard Schabath, Richard Ratei, Andrea Stroux, Claus-Detlev Klemke, Antje van Lessen

Hematol Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.
Anne Flörcken, Joachim Kopp, Antje van Lessen, Kamran Movassaghi, Anna Takvorian

Hum Vaccin Immunother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-leukemia T cells in AML: TNF-α⁺ CD8⁺ T cells may escape detection and possibly reflect a stage of functional impairment.
Anne Flörcken, Antje van Lessen, Theis H Terwey, Bernd Dörken, Renate Arnold

Hum Vaccin Immunother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Anne Flörcken, Anna Takvorian, Antje Van Lessen, Anju Singh, Werner Hopfenmüller

Anticancer Drugs· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Jörg Westermann, Joachim Kopp, Antje van Lessen, Ann-Christine Hecker, Gökben Baskaynak

Br J Haematol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
Jörg Westermann, Georg Maschmeyer, Antje van Lessen, Bernd Dörken, Antonio Pezzutto

Int J Hematol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis